Balancing NAD Deficits with Nicotinamide Riboside: Therapeutic Possibilities and Limitations

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2022 Aug 2

PMID 35918544

Authors

Angelique Cercillieux

Eleonora Ciarlo

Carles Canto

Affiliations

Soon will be listed here.

Abstract

Alterations in cellular nicotinamide adenine dinucleotide (NAD) levels have been observed in multiple lifestyle and age-related medical conditions. This has led to the hypothesis that dietary supplementation with NAD precursors, or vitamin B3s, could exert health benefits. Among the different molecules that can act as NAD precursors, Nicotinamide Riboside (NR) has gained most attention due to its success in alleviating and treating disease conditions at the pre-clinical level. However, the clinical outcomes for NR supplementation strategies have not yet met the expectations generated in mouse models. In this review we aim to provide a comprehensive view on NAD biology, what causes NAD deficits and the journey of NR from its discovery to its clinical development. We also discuss what are the current limitations in NR-based therapies and potential ways to overcome them. Overall, this review will not only provide tools to understand NAD biology and assess its changes in disease situations, but also to decide which NAD precursor could have the best therapeutic potential.

Citing Articles

Urolithin A and nicotinamide riboside differentially regulate innate immune defenses and metabolism in human microglial cells.

Madsen H, Navarro C, Gasparini E, Park J, Li Z, Croteau D Front Aging Neurosci. 2024; 16:1503336.

PMID: 39665042 PMC: 11631940. DOI: 10.3389/fnagi.2024.1503336.

NAD enhancers as therapeutic agents in the cardiorenal axis.

Marin-Blazquez M, Rovira J, Ramirez-Bajo M, Zapata-Perez R, Rabadan-Ros R Cell Commun Signal. 2024; 22(1):537.

PMID: 39516787 PMC: 11546376. DOI: 10.1186/s12964-024-01903-4.

Erythrocyte nicotinamide adenine dinucleotide concentration is enhanced by systematic sports participation.

Pospieszna B, Kusy K, Slominska E, Zielinski J, Ciekot-Soltysiak M BMC Sports Sci Med Rehabil. 2024; 16(1):216.

PMID: 39407226 PMC: 11476931. DOI: 10.1186/s13102-024-00999-y.

NAD metabolism and heart failure: Mechanisms and therapeutic potentials.

Walker M, Tian R J Mol Cell Cardiol. 2024; 195:45-54.

PMID: 39096536 PMC: 11390314. DOI: 10.1016/j.yjmcc.2024.07.008.

Metabolomic analysis of the human placenta reveals perturbations in amino acids, purine metabolites, and small organic acids in spontaneous preterm birth.

Cifkova E, Karahoda R, Stranik J, Abad C, Kacerovsky M, Lisa M EXCLI J. 2024; 23:264-282.

PMID: 38487084 PMC: 10938235. DOI: 10.17179/excli2023-6785.

References

Camacho-Pereira J, Tarrago M, Chini C, Nin V, Escande C, Warner G . CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23(6):1127-1139. PMC: 4911708. DOI: 10.1016/j.cmet.2016.05.006. View

Essuman K, Summers D, Sasaki Y, Mao X, DiAntonio A, Milbrandt J . The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. 2017; 93(6):1334-1343.e5. PMC: 6284238. DOI: 10.1016/j.neuron.2017.02.022. View

Mateuszuk L, Campagna R, Kutryb-Zajac B, Kus K, Slominska E, Smolenski R . Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. Biochem Pharmacol. 2020; 178:114019. DOI: 10.1016/j.bcp.2020.114019. View

Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L . The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012; 483(7388):218-21. DOI: 10.1038/nature10815. View

Lu J, Yu C, Wu M . Pellagra in an immunocompetent patient with cytomegalovirus colitis. Am J Gastroenterol. 2001; 96(3):932-4. DOI: 10.1111/j.1572-0241.2001.03659.x. View

Zhou C, Yang X, Hua X, Liu J, Fan M, Li G . Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016; 173(15):2352-68. PMC: 4945761. DOI: 10.1111/bph.13513. View

Frederick D, Loro E, Liu L, Davila Jr A, Chellappa K, Silverman I . Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016; 24(2):269-82. PMC: 4985182. DOI: 10.1016/j.cmet.2016.07.005. View

Liszt G, Ford E, Kurtev M, Guarente L . Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem. 2005; 280(22):21313-20. DOI: 10.1074/jbc.M413296200. View

Dollerup O, Christensen B, Svart M, Schmidt M, Sulek K, Ringgaard S . A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018; 108(2):343-353. DOI: 10.1093/ajcn/nqy132. View

10.

Conforti L, Janeckova L, Wagner D, Mazzola F, Cialabrini L, Di Stefano M . Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration. FEBS J. 2011; 278(15):2666-79. DOI: 10.1111/j.1742-4658.2011.08193.x. View

11.

Zhai R, Rizzi M, Garavaglia S . Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, new insights into an ancient enzyme. Cell Mol Life Sci. 2009; 66(17):2805-18. PMC: 11115848. DOI: 10.1007/s00018-009-0047-x. View

12.

Kropotov A, Kulikova V, Nerinovski K, Yakimov A, Svetlova M, Solovjeva L . Equilibrative Nucleoside Transporters Mediate the Import of Nicotinamide Riboside and Nicotinic Acid Riboside into Human Cells. Int J Mol Sci. 2021; 22(3). PMC: 7866510. DOI: 10.3390/ijms22031391. View

13.

Barbosa M, Soares S, Novak C, Sinclair D, Levine J, Aksoy P . The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 2007; 21(13):3629-39. DOI: 10.1096/fj.07-8290com. View

14.

Yaku K, Palikhe S, Izumi H, Yoshida T, Hikosaka K, Hayat F . BST1 regulates nicotinamide riboside metabolism via its glycohydrolase and base-exchange activities. Nat Commun. 2021; 12(1):6767. PMC: 8604996. DOI: 10.1038/s41467-021-27080-3. View

15.

Pan P, Feldman J, Devries M, Dong A, Edwards A, Denu J . Structure and biochemical functions of SIRT6. J Biol Chem. 2011; 286(16):14575-87. PMC: 3077655. DOI: 10.1074/jbc.M111.218990. View

16.

Trammell S, Weidemann B, Chadda A, Yorek M, Holmes A, Coppey L . Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Sci Rep. 2016; 6:26933. PMC: 4882590. DOI: 10.1038/srep26933. View

17.

Osterloh J, Yang J, Rooney T, Fox A, Adalbert R, Powell E . dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012; 337(6093):481-4. PMC: 5225956. DOI: 10.1126/science.1223899. View

18.

Doig C, Zielinska A, Fletcher R, Oakey L, Elhassan Y, Garten A . Induction of the nicotinamide riboside kinase NAD salvage pathway in a model of sarcoplasmic reticulum dysfunction. Skelet Muscle. 2020; 10(1):5. PMC: 7031948. DOI: 10.1186/s13395-019-0216-z. View

19.

Lunn E, Perry V, Brown M, Rosen H, Gordon S . Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J Neurosci. 1989; 1(1):27-33. DOI: 10.1111/j.1460-9568.1989.tb00771.x. View

20.

Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh V, Ferrero E . CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom. 2013; 84(4):207-17. DOI: 10.1002/cyto.b.21092. View